Case Studies/How a Wellness Brand Launched a White-Label GLP-1 Program in Weeks
Case studySuccess MetricsCase StudyGLP-1Wellness
FUSE Health · 6 min read · March 27, 2026

How a Wellness Brand Launched a White-Label GLP-1 Program in Weeks

How a wellness brand launched a white-label GLP-1 program in weeks
TLDR

A white-label GLP-1 program took this wellness brand from no clinical setup to live sales in weeks. LegitScript and healthcare payments cleared before launch, refills ran from the first patient, and by day 90 refill revenue had overtaken first-purchase revenue.

This direct-to-consumer wellness brand had 80,000 people on its email list and a reputation built on metabolic health content. Its subscribers kept asking about semaglutide and GLP-1 programs by name.

So the demand was there. What the brand lacked was everything a prescription program runs on: licensed providers, pharmacy contracts, HIPAA-ready data handling and a payment processor willing to bill for healthcare subscriptions.

It launched its own white-label GLP-1 program on FUSE Health in weeks. Here's how each piece was set up and what the revenue mix looked like at day 90.

Executive Summary

ItemDetail
ClientDirect-to-consumer wellness brand focused on metabolic health, with 80,000 email subscribers
What launchedA white-label GLP-1 program, sold under the brand's own name on FUSE Health
Time to launchWeeks, against an in-house estimate of 14 to 18 months
Ready at launchLegitScript certification, healthcare-approved payment processing, refill and payment recovery flows
Clinical modelIndependent licensed clinicians review every intake; licensed partner pharmacies dispense
Day-90 resultMonthly refill revenue exceeded first-purchase revenue

The Challenge

Nobody on the brand's team had run a clinical operation. They had no plans to hire a clinical director, and they didn't want to spend months negotiating pharmacy agreements before selling a single subscription.

They priced out two other routes first.

RouteWhat it involvedWhy it didn't fit
Build it in-houseA healthcare attorney estimated 14 to 18 months: provider credentialing in each target state, pharmacy contracts, HIPAA architecture and LegitScript certification, which the estimate put at 60 to 90 days on its ownMore than a year before the first sale
Clinical-review-only platformProvider review, with no pharmacy integration or subscription billingThree vendors to manage from day one, and overhead the team expected to eat most of the margin

What the brand wanted was one setup where it sold the program and the regulated work ran behind the storefront.

Where GLP-1 Launches Usually Stall

In the GLP-1 telehealth launches we support, the storefront is rarely what slows things down. The delays come from three places.

  • Ads that can't run. Meta requires LegitScript certification before telehealth providers can promote prescription drugs, and Google requires a telemedicine certification too. Apply after launch and the first weeks pass without paid traffic.
  • A processor that won't bill. Many standard merchant accounts decline healthcare subscription billing, and brands often find out when the first charges fail.
  • Refills left to the patient. If every renewal depends on someone remembering to reorder, revenue resets each month and the brand ends up paying to win back customers it already had.

This brand dealt with all three before its first order.

How the Program Launched, Step by Step

The brand sold the GLP-1 program. Clinical decisions sat with independent licensed clinicians, dispensing sat with licensed pharmacies, and FUSE Health's white-label telehealth platform connected the storefront to both. Here's what each piece did.

Intake and eligibility screening step in a white-label GLP-1 program

1. Storefront and Intake

Patients bought through the brand's own storefront, under its own name. The intake form was built around the clinical criteria in the prescribing protocol, so people who didn't qualify were screened out before a clinician saw their file. Clinician time went only to eligible submissions.

2. Clinician Review

Eligible submissions went to independent licensed clinicians through an asynchronous review workflow with a defined turnaround. Every prescribing decision was the clinician's.

Operators usually ask two things here: does the brand need a medical license, and does it see patient records? This one needed neither. It had no access to individual patient health data, which stayed on the clinical side of the platform. State rules on who can own or direct a medical practice do vary, so check the CPOM rules for every state you plan to sell in.

3. Pharmacy Fulfillment

Approved prescriptions went through automatic pharmacy routing to a licensed partner pharmacy, which dispensed and shipped straight to the patient. Which medication a patient received, FDA-approved or compounded, was the prescriber's call under the federal and state rules in force at the time. Nobody at the brand touched a prescription or a pharmacy order.

4. Refills and Payment Recovery

Subscription refills were configured before the first patient enrolled. When a cycle ended, the next supply started automatically, so patients stayed on the program without reordering by hand. Failed payments, expiring cards and lapsed refills each had a recovery flow in place before go-live, and nobody on the team had to chase them.

Subscription refill and payment recovery setup for a GLP-1 program

5. LegitScript and Payments Before Go-Live

Certification sat inside the pre-launch plan, so the brand could run paid campaigns on Google and Meta from launch day. Payment processing approved for healthcare subscription billing was confirmed before the first charge went through.

GLP-1 Program Results After 90 Days

  • Live in weeks, against an in-house estimate of 14 to 18 months.
  • LegitScript certification was in place at launch, so paid acquisition started on day one.
  • Refills and payment recovery were running before the first patient enrolled.
  • Brand staff never handled a prescription or a pharmacy order.
  • Within 90 days, monthly recurring revenue from refills was higher than revenue from first purchases.

That last result is the one I'd point other operators to. First-purchase revenue rises and falls with ad spend. Refill revenue builds with every cohort that stays. When refills pass new sales inside one quarter, most of the program's revenue is coming from customers it has already paid to acquire.

What It Costs to Run

We publish our pricing, so here's what a brand launching a white-label GLP-1 program would pay today. The Growth plan is $5,600 upfront, which covers expedited LegitScript coordination and the first month, then $699 a month from month two. There's a 2% merchant fee on patient payments processed through FUSE Health and no per-visit or per-prescription fees.

Our breakdown of telehealth revenue models compares this with the other ways to run a program.

Regulatory Note

GLP-1 rules changed fast between 2024 and 2026. FDA declared the tirzepatide shortage resolved on December 19, 2024, and the semaglutide shortage resolved on February 21, 2025. Its guidance, current as of April 1, 2026, states that neither drug appears on the 503B bulks list or on FDA's drug shortage list. If you're weighing pharmacy types, see 503A vs 503B. On advertising, Google is adding NABP accreditation as a second route to telemedicine certification from November 2026, alongside LegitScript.

This case study describes one brand's launch. It isn't medical or legal advice, and it makes no claims about treatment outcomes for any patient. FUSE Health provides the technology and does not configure or provide medical treatment. Get qualified healthcare counsel before launching a GLP-1 program.

What This Means for Your Launch

The brand brought an audience that already trusted it. Everything regulated was in place behind the storefront before the first order: certification, healthcare payments, clinician review, pharmacy routing and refills. That order of work is why paid traffic started on day one, and why refills had overtaken new sales by day 90.

If you have the audience and your subscribers are already asking, the next step is a launch plan for your own white-label GLP-1 program, with a date on it. Book a demo and we'll build that plan with you.

References

  1. FDA, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (content current as of April 1, 2026)
  2. FDA, Tirzepatide Declaratory Order (December 19, 2024)
  3. FDA, Semaglutide Declaratory Order (February 21, 2025)
  4. Meta Transparency Center, Advertising Standards: Drugs and pharmaceuticals
  5. Search Engine Roundtable, Google Ads Gains A New Telemedicine Certification Option (NABP, November 2026)
  6. LegitScript Healthcare Merchant Certification
  7. FUSE Health pricing (checked November 10, 2026)
Daniel Meursing
Daniel Meursing
CEO

Daniel is a two-time founder who has scaled service businesses across major U.S. markets. A Y Combinator competition winner, he focuses on removing operational and regulatory barriers so operators can build and scale modern healthcare businesses.

Background
Startup Operations & Service Systems
Experience
2x Founder, Multi-Market U.S. Scaling
Qualifications
Healthtech Market Expertise & Operational Scaling
Key Achievement
Scaled Premier Staff & Eventstaff across major U.S. markets

Frequently Asked Questions

How long does it take to launch a white-label GLP-1 program?

This brand launched in weeks. On FUSE Health's Partner plan, brands can go live in as little as 3 days once brand materials, agreements, payment setup, required approvals and pharmacy readiness are complete. Timing depends on third parties and isn't guaranteed.

Does a wellness brand need a medical license to offer a GLP-1 program?

No. Independent licensed clinicians review each intake and make every prescribing decision, and licensed pharmacies dispense. Corporate practice of medicine rules differ by state, so confirm your structure for each state you sell into.

How long does LegitScript certification take?

FUSE-coordinated LegitScript applications take an estimated 11 days to approval on average. LegitScript reviews and decides every application independently, so approval and timing aren't guaranteed. You'll want it before launch: Meta requires it for telehealth providers promoting prescription drugs, and Google requires LegitScript or, from November 2026, NABP accreditation for telemedicine ads.

Does the brand see patient health data?

No. In this GLP-1 program the brand had no access to individual patient health data. Intake answers and clinical records stayed on the clinical side of the platform, while the brand ran its storefront, content and acquisition.

Can we use our existing payment processor?

Often not. Many standard merchant accounts decline healthcare subscription billing, so confirm your processor approves this category before the first charge. This brand had its payment setup confirmed before launch. On FUSE Health's Growth and Partner plans, the merchant fee is 2%.

Building a Peptide Brand?

See how FUSE infrastructure can help you launch and scale a compliant program faster.